An updated review on cancer risk associated with incretin mimetics and enhancers. - Wikidata - wikimedia - TriplyDB

An updated review on cancer risk associated with incretin mimetics and enhancers.

An updated review on cancer risk associated with incretin mimetics and enhancers.

http://www.wikidata.org/entity/Q38388920

about

Use of Insulin and Mortality from Breast Cancer among Taiwanese Women with Diabetes Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.Factors Associated with Cancer- and Non-Cancer-Related Deaths among Taiwanese Patients with Diabetes after 17 Years of Follow-Up Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes.Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus.Sitagliptin and heart failure hospitalization in patients with type 2 diabetes Metformin use and cervical cancer risk in female patients with type 2 diabetes Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes.The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes.Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.Cardiovascular safety and benefits of GLP-1 receptor agonists.Sitagliptin and oral cancer risk in type 2 diabetes patients.Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.

P2860

Q35782192-3F0C8175-C768-4C69-B3C5-79B41ED650A5 Q36050559-9D98C6DE-FAA9-4203-858B-39A87B58F7A9 Q36209639-F7777543-8155-4B6E-999F-2CE9BBFAF14D Q37269476-9AE3A779-66CA-43EC-A395-8617F33D6356 Q37274957-F10623D9-CF73-49CD-B028-262F915F1074 Q37641835-9C498AC0-79B1-44D8-82B8-2DCC99DA536D Q37644891-5771AE44-7455-4B59-AF8A-6DD2F4D6E275 Q37745926-48CD7B10-660B-42B0-B6F6-0BAC216AABEA Q38820260-A839F8C0-B324-4664-95CD-310443BA219D Q38941094-C7E397CA-31FA-4258-8E1E-AAA929A7D127 Q38989517-F94E77CF-6806-4AE4-899C-B1C0BDC46D3A Q39013056-03536C1E-93B6-44BF-84BD-6A5F57B3137B Q47096984-206B1161-227C-493D-900D-769CF62B7B46 Q47687852-A39EE5F1-F093-4D55-A175-FCDF8DD18CEE

P2860

An updated review on cancer risk associated with incretin mimetics and enhancers.

http://www.wikidata.org/entity/Q38388920

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

An updated review on cancer risk associated with incretin mimetics and enhancers.

@en

type

label

An updated review on cancer risk associated with incretin mimetics and enhancers.

@en

prefLabel

An updated review on cancer risk associated with incretin mimetics and enhancers.

@en

P1433

Q38388920-C1BAD931-59D7-4DDC-9C8B-7B955F7988D0

P1476

Q38388920-A70389DC-5AD8-4313-B6CA-C23933E0F080

P2093

Q38388920-2DFA0D7F-4F3C-4781-A7FB-7E6DC64F0BD2

Q38388920-3A2B37B0-7E74-4ABC-B997-98856B5C347F

Q38388920-FF531F55-D0D7-4E39-9399-946DB5DE4412

P2860

Q38388920-00433226-024E-4525-9140-59FF61CE9E40

Q38388920-042F2907-D10A-4958-A79E-E58EDE2D1054

Q38388920-0444732D-8E5D-424E-B706-039234171385

Q38388920-064E2F85-452E-445A-8F56-64AEB412AD49

Q38388920-0656FBFB-40A7-4EF5-9232-1FF882B32899

Q38388920-07805DAA-3FDD-481F-9401-B604C859BD6A

Q38388920-08D5DAE7-C375-47AC-BA1A-E3759E1560C6

Q38388920-08DE9FC5-4071-4844-AC72-8B91EE997551

Q38388920-0999A9DD-B758-4F4F-AA3A-49B53158F165

Q38388920-0B620E07-6040-4EAE-BED1-9BBA22626266

P304

Q38388920-6D175FF0-E40B-4EC4-8767-515AA0B5FBDD

P31

Q38388920-DF5DD33D-3A67-4E6F-8675-E45F43F734C6

P356

Q38388920-7DCF98FE-085F-413C-B234-A1407842B24C

P433

Q38388920-9E8350D1-F243-4174-9A79-DB47262EB70B

P478

Q38388920-8A90BD09-5AF1-429F-AD86-FA50A7A71392

P577

Q38388920-B1AB3D5A-E47E-44DC-BBDC-E0A6A0E94E3F

P698

Q38388920-112F1D39-7414-4F28-AB97-567D75F1B431

P356

10590501.2015.1003496

P1433

Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews

P1476

An updated review on cancer risk associated with incretin mimetics and enhancers.

@en

P2093

Chin-Hsiao Tseng

http://www.w3.org/2001/XMLSchema#string

Farn-Hsuan Tseng

http://www.w3.org/2001/XMLSchema#string

Kuo-Yang Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

Diabetes and gastric cancer: the potential links

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

Do incretin-based therapies cause acute pancreatitis?

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

On the Origin of Cancer Cells

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

P304

67-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10590501.2015.1003496

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25803196

http://www.w3.org/2001/XMLSchema#string